米力农在风湿性心脏瓣膜病心功能不全中的应用价值(2)
第1页 |
参见附件(1842KB,2页)。
[2]颜红兵,柯元南.美国成人慢性心力衰竭诊断与治疗指南(2005年修订版)[M].北京:中国环境科学出版社,2005:7.
[3]华伟.心力衰竭非药物治疗的现状与发展方向[J].中华医学杂志,2006,86:1083-1085.
[4]Rosamond W,Flegal K,Friday G,et al.Heart disease and stroke statistics-2007 update:A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee[J].Circulation,2007,115(5):169-171.
[5]苏立杰,李觉,胡大一.心衰的研究现状和进展[J].中国心血管病研究,2009,7(3):222-225.
[6]Toma M,Starling RC.Inotropic therapy for end-stage heart failure patients[J].Curr Treat Options Cardiovasc Med,2010,12(5):409-419.
[7]Jennings DL,Thompson ML.Use of combination therapy with a beta-blocker and milrinone in patients with advanced heart failure[J].Ann Pharmacother,2009,43(11):1872-1876.
[8]Jebeli M,Ghazinoor M,Mandegar MH,et al.Effect of milrinone on short-term outcome of patients with myocardial dysfunction under going coronary artery bypass graft:A randomized controlled trial[J].Cardiol J,2010(1):73-78.
[9]Tisdale JE,Patel R,Webb CR,et al.Electrophysiologic and proarrhythmic effects of intravenous inotropic agents[J].Prog cardiovasc Dis,1999,38:167-180.
作者简介:强丽丽(1974—),女,毕业于承德医学院,主治医师,现工作于山西省柳林县人民医院 (邮编:033300);高婧、 薛爱萍、宋瑞芳、车翠珍,工作于山西省柳林县人民医院。
(收稿日期:2010-12-22)
(本文编辑王雅洁)
您现在查看是摘要介绍页,详见PDF附件(1842KB,2页)。